Companies HilleVax, Inc.
HilleVax CEO salary & total pay, FY2024: $6.7M
HilleVax (HLVX) CEO salary, fiscal 2024: Robert Hershberg was paid a salary of $666,750 and $6,734,876 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me HilleVax, Inc.’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Robert Hershberg's complete compensation dossier
A PDF and a CSV sent to your email: Robert Hershberg's pay in every fiscal year HilleVax, Inc. reported it, line by line, with Robert Hershberg's equity grants and HilleVax, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $9,697,495FY2023
- $6,734,876FY2024
CEO total pay was $6,734,876 in fiscal 2024, down from $9,697,495 in fiscal 2023.
FY2024: salary $666,750 · bonus $0 · stock awards $2,623,482 · option awards $3,416,888
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Robert Hershberg | $666,750 | $0 | $2,623,482 | $3,416,888 | $0 | $0 | $27,756 | $6,734,876 |
| Chairman, President and Chief Executive Officer | ||||||||
| Sean McLoughlin | 450,000 | 0 | 0 | 3,542,500 | 0 | 0 | 544,315 | 4,536,815 |
| Former Chief Operating Officer | ||||||||
| Aditya Kohli | 500,000 | 0 | 826,764 | 1,076,790 | 0 | 0 | 626,977 | 3,030,531 |
| Former Chief Business Officer and former Chief Operating Officer | ||||||||
| Shane Maltbie | 473,000 | 0 | 715,681 | 932,124 | 0 | 0 | 39,375 | 2,160,180 |
| Chief Financial Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Robert Hershberg | $6,734,876 | $9,697,495 | — | ↓ −2,962,619 |
| Sean McLoughlin | 4,536,815 | — | — | — |
| Aditya Kohli | 3,030,531 | 4,076,137 | — | ↓ −1,045,606 |
| Shane Maltbie | 2,160,180 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The company's compensation program is designed to align the interests of employees and executive officers with those of stockholders. Equity-based incentive awards are the primary vehicle for long-term alignment, granted under the 2022 Incentive Award Plan to new hires and for ongoing employees.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
Equity grants and outstanding awards
No plan-based awards are on file for this fiscal year.
Outstanding equity awards at fiscal year-end 2024
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Aditya Kohli | Option | 82,795 | — | 18 | — |
| Aditya Kohli | Option | 28,302 | — | 15.06 | — |
| Robert Hershberg | RSU | — | 24,295 | — | 50,291 |
| Robert Hershberg | RSU | — | 140,975 | — | 291,818 |
| Robert Hershberg | Option | — | 175,060 | 18 | — |
| Robert Hershberg | RSU | — | 174,202 | — | 260,598 |
| Robert Hershberg | Option | — | 226,885 | 15.06 | — |
| Sean McLoughlin | Option | 98,958 | — | 14.17 | — |
| Shane Maltbie | Option | 69,341 | 23,114 | 6.99 | — |
| Shane Maltbie | Option | 11,557 | 5,253 | 8.05 | — |
| Shane Maltbie | RSU | — | 32,500 | — | 67,275 |
| Shane Maltbie | Option | 29,791 | 35,209 | 18 | — |
| Shane Maltbie | RSU | — | 47,522 | — | 98 |
| Shane Maltbie | Option | — | 61,894 | 15.06 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Patrick HeronIndependent · Audit · Nominating and Corporate Governance (Chair) | $79,041 | — | $309,375 | — | $0 | $388,416 |
| Julie Gerberding, M.D., M.P.HIndependent · Compensation (Chair) · Nominating and Corporate Governance | 63,962 | — | 309,375 | — | 0 | 373,337 |
| Nanette Cocero, Ph.DIndependent · Audit · Nominating and Corporate Governance | 59,464 | — | 309,375 | — | 0 | 368,839 |
| Shelley Chu, M.D., Ph.DIndependent · Compensation | 52,540 | — | 309,375 | — | 0 | 361,915 |
| Jaime Sepulveda, M.D., D.Sc., M.P.HIndependent · Nominating and Corporate Governance | 50,255 | — | 309,375 | — | 0 | 359,630 |
| Robert Hershberg, M.D., Ph.DEmployee director · Board Chair | — | — | — | — | — | 0 |
| Aditya Kohli, Ph.DNot independent | — | — | — | — | — | 0 |
| Gary Dubin, M.DNot independent | 0 | — | 0 | — | 0 | 0 |
| Jeryl HillemanIndependent · Audit (Chair) · Compensation | 72,540 | — | 309,375 | — | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 15,000 / 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $377,802 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $377,802 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names HilleVax as a peer
Companies that benchmark against HLVX
No companies currently name HLVX as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | HilleVax, Inc. | 2024 | Robert Hershberg | $666,750 | $2,623,482 | $3,416,888 | $0 | $6,734,876 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-06-23 | — | — | — | — | — |
| 2024 | 2024-06-06 | — | — | — | — | — |
| 2023 | 2023-06-07 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-06-23 | —a |
| 2024 | 2024-06-06 | —b |
| 2023 | 2023-06-07 | —c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Voting standard not stated in the filing.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jeryl Hilleman | Director | 2025-06-23 | A | 17,199 | $0 | $0 | Common | Form 4 ↗ |
| Gary Dubin | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Julie L. Gerberding | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Nanette Cocero | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Jaime Sepulveda | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Shelley Chu | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Aditya Kohli | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Patrick Heron | Director | 2025-06-23 | A | 17,199 | 0 | 0 | Common | Form 4 ↗ |
| Jaime Sepulveda | Director | 2025-09-17 | D | 59,224 | — | — | Common | Form 4 ↗ |
| Shane Maltbie | Chief Financial Officer | 2025-09-17 | D | 83,738 | — | — | Common | Form 4 ↗ |
| Julie L. Gerberding | Director | 2025-09-17 | D | 59,224 | — | — | Common | Form 4 ↗ |
| Aditya Kohli | Director | 2025-09-17 | D | 698,171 | — | — | Common | Form 4 ↗ |
| Gary Dubin | Director | 2025-09-17 | D | 17,199 | — | — | Common | Form 4 ↗ |
| Shelley Chu | Director | 2025-09-17 | D | 17,199 | — | — | Common | Form 4 ↗ |
| Jeryl Hilleman | Director | 2025-09-17 | D | 59,224 | — | — | Common | Form 4 ↗ |
| Robert Hershberg | Director | 2025-09-17 | D | 1,101,498 | — | — | Common | Form 4 ↗ |
| Nanette Cocero | Director | 2025-09-17 | D | 17,199 | — | — | Common | Form 4 ↗ |
| Frazier Life Sciences X, L.P. | Greater-than-10% holder | 2025-09-17 | D | 17,199 | 2 | 33,538 | Common | Form 4 ↗ |
| Frazier Life Sciences X, L.P. | Greater-than-10% holder | 2025-09-17 | D | 8,535,337 | 2 | 16,643,907 | Common | Form 4 ↗ |
| TAKEDA PHARMACEUTICAL CO LTD | Greater-than-10% holder | 2025-09-17 | D | 6,724,000 | 2 | 13,111,800 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (39 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Robert Hershberg. DEF 14A, filed 2025-04-30. Section “Executive Compensation” · page 23. As printed: 6,734,876. View filing ↗
- Section 01, Sean McLoughlin. DEF 14A, filed 2025-04-30. Section “Executive Compensation”. As printed: 4,536,815. View filing ↗
- Section 01, Aditya Kohli. DEF 14A, filed 2025-04-30. Section “Executive Compensation”. As printed: 3,030,531. View filing ↗
- Section 01, Shane Maltbie. DEF 14A, filed 2025-04-30. Section “Executive Compensation”. As printed: 2,160,180. View filing ↗
- Section 08, Patrick Heron. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 388,416. View filing ↗
- Section 08, Julie Gerberding, M.D., M.P.H. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 373,337. View filing ↗
- Section 08, Nanette Cocero, Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 368,839. View filing ↗
- Section 08, Shelley Chu, M.D., Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 361,915. View filing ↗
- Section 08, Jaime Sepulveda, M.D., D.Sc., M.P.H. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 359,630. View filing ↗
- Section 08, Robert Hershberg, M.D., Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Aditya Kohli, Ph.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Gary Dubin, M.D. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 08, Jeryl Hilleman. DEF 14A, filed 2025-04-30. Section “Director Compensation”. As printed: —. View filing ↗
- Section 02, Jeryl Hilleman 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Dubin 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie L. Gerberding 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nanette Cocero 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jaime Sepulveda 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelley Chu 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aditya Kohli 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Patrick Heron 2025-06-23. Form 4, filed 2025-06-25. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jaime Sepulveda 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shane Maltbie 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Julie L. Gerberding 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Aditya Kohli 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Gary Dubin 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Shelley Chu 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jeryl Hilleman 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Robert Hershberg 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Nanette Cocero 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frazier Life Sciences X, L.P. 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Frazier Life Sciences X, L.P. 2025-09-17. Form 4, filed 2025-09-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, TAKEDA PHARMACEUTICAL CO LTD 2025-09-17. Form 4, filed 2025-09-19. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-25. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-10. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-13. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 09b board cost (computed). Computed. Cash 377,802 + equity 0 + all other 0 = 377,802, summed across the director compensation table rows.
- HilleVax, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-30. CEO total compensation as printed in HilleVax, Inc.'s own proxy. As printed: 6,734,876. View filing ↗